TABLE 1.
Prevented fraction based on persistent antigenemia
| Group | Treatment | Persistent antigenemia (%) | Prevented fraction (%)a |
|---|---|---|---|
| A | Nobivac feline 2-FeLV | 0 | 100 |
| B | PureVax recombinant FeLV | 50 | 45 |
| C | Placebo control | 91 |
a
Prevented fraction was calculated for all groups using the equation 1 − [(incidence of persistent antigenemia in vaccinates)/(incidence of persistent antigenemia in controls)]. Statistically significant differences in protection were seen when the Nobivac feline 2-FeLV group was compared to the control group and to the PureVax recombinant FeLV group (P < 0.0001 and P = 0.0124, respectively). There was no significant difference between the PureVax recombinant FeLV group and the control group (P = 0.0635).